Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 4/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | CCNK | O75909 | 3/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4281659 | 0.99 | GSK3B (0.48) | GSK3BJAK3JAK2CCR6EGLN2 | |
| SCHEMBL4287388 | 0.87 | GSK3B (0.51) | GSK3BJAK3JAK2EGLN2CDK2 | |
| SCHEMBL1919861 | 0.85 | JAK3 (0.46) | GSK3BJAK3JAK2CCR6DPP4 | |
| SCHEMBL4284030 | 0.82 | GSK3B (0.70) | GSK3B | |
| SCHEMBL12680860 | 0.80 | CCR6 (0.43) | GSK3BJAK3JAK2CCR6EGLN2 | |
| SCHEMBL8143524 | 0.80 | GSK3B (0.53) | GSK3BJAK3JAK2CCR6CCNK | |
| SCHEMBL2935250 | 0.80 | JAK3 (0.42) | GSK3BJAK3JAK2CCR6CCNK | |
| SCHEMBL8037163 | 0.80 | GSK3B (0.47) | GSK3B | |
| Hydrochloric Acid SCHEMBL4281336 | 0.79 | GSK3B (0.46) | GSK3B | |
| SCHEMBL10270187 | 0.77 | CCR6 (0.43) | GSK3BJAK3JAK2CCR6EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | GSK3B 2707/4885JAK3 269/4885JAK2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.